Effect of postoperative radiotherapy after complete resection in patients with stage ⅢA-N2 non-small cell lung cancer: A propensity score matching analysis
- VernacularTitle:术后放疗对ⅢA-N2期非小细胞肺癌患者预后影响的倾向性评分匹配研究
- Author:
Zhengshui XU
1
,
2
;
Minxia ZHU
1
,
2
;
Jiantao JIANG
1
,
2
;
Shiyuan LIU
1
,
2
;
Jia CHEN
3
;
Danjie ZHANG
1
,
2
;
Jianzhong LI
1
,
2
;
Liangzhang SUN
1
,
2
;
Shaomin LI
1
,
2
Author Information
1. Department of Thoracic Surgery, The Second Affiliated Hospital of Xi'
2. an Jiaotong University, Xian, 710004, P. R. China
3. Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xian, 710032, P. R. China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
postoperative radiotherapy;
complete resection;
chemotherapy;
propensity score matching analysis
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(07):1006-1012
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the value of postoperative radiotherapy (PORT) in patients with stage ⅢA-N2 non-small cell lung cancer who received complete resection and chemotherapy. Methods Patients with stage ⅢA-N2 non-small cell lung cancer who received complete resection and chemotherapy were chosen from the SEER Research Plus Database [17 Registries, November 2012 Submission (2000-2019)]. The patients were divided into a PORT group and a non-PORT group according to whether the PORT was used. To balance baseline characteristics between non-PORT and PORT groups, R software was used to conduct a propensity score matching (PSM) with a ratio of 1 : 1 and a matching tolerance of 0.01. Both the Cox regression analysis and Kaplan-Meier survival analysis were conducted to evaluate the value of PORT in terms of overall survival (OS) and disease-specific survival (DSS). Results In total, 2468 patients with stage ⅢA-N2 non-small cell lung cancer were enrolled, including 1078 males and 1390 females with a median age of 65 (58-71) years. There were 1336 patients in the PORT group, and 1132 patients in the non-PORT group. Cox regression analysis showed that PORT was not significantly associated with OS (multivariate analysis: HR=1.051, 95%CI 0.949-1.164, P=0.338) and DSS (multivariate analysis: HR=1.094, 95%CI 0.976-1.225, P=0.123). No statistical difference was found in the OS or DSS between non-PORT group and PORT group after PSM analysis (P＞0.05). Conclusion PORT does not have a survival benefit for patients with stage ⅢA-N2 non-small cell lung cancer who received complete resection and chemotherapy.
